Comparison 4. Adalimumab versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 IBDQ at week 8	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2 IBDQ at week 52	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 Improved IBDQ (≥16 points from baseline) at week 8	2	767	Risk Ratio (M‐H, Fixed, 95% CI)	1.23 [1.06, 1.43]
4 Improved IBDQ (≥16 points from baseline) at week 52	2	767	Risk Ratio (M‐H, Fixed, 95% CI)	1.73 [1.28, 2.34]